Corticosteroid injections for knee osteoarthritis offer clinical benefits similar to hyaluronic acid and lower than platelet-rich plasma: a systematic review and meta-analysis.

Autor:	Bensa A; Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland., Sangiorgio A; Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland., Boffa A; Applied and Translational Research (ATR) Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Salerno M; Applied and Translational Research (ATR) Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Moraca G; Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland., Filardo G; Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Lugano, Switzerland.; Applied and Translational Research (ATR) Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.; Università della Svizzera Italiana, Faculty of Biomedical Sciences, Lugano, Switzerland.
Jazyk:	angličtina
Zdroj:	EFORT open reviews [EFORT Open Rev] 2024 Sep 02; Vol. 9 (9), pp. 883-895. Date of Electronic Publication: 2024 Sep 02.
DOI:	10.1530/EOR-23-0198
Abstrakt:	Purpose: Intra-articular corticosteroid (CS) injections for knee osteoarthritis (OA) management are endorsed by several scientific societies, while the use of hyaluronic acid (HA) and platelet-rich plasma (PRP) is more controversial. Aim of the study was to quantify and compare the clinical effectiveness of CS injections with respect to HA and PRP in patients with knee OA. Methods: The search was conducted on PubMed, Cochrane, and Web of Science following the PRISMA guidelines. Randomized controlled trials (RCTs) on the comparison of CS injections and HA or PRP injections for the treatment of knee OA were included. The minimal clinically important difference (MCID) was used to interpret the clinical relevance of the improvements at different follow-ups up to 12 months. The study quality was assessed using the Cochrane RoB-2 tool and the GRADE guidelines. Results: Thirty-five RCTs were included (3348 patients). The meta-analysis comparing CS and HA revealed no difference in terms of WOMAC improvement, while HA showed superior VAS pain improvement at long-term follow-up (P = 0.011), without reaching the MCID. PRP offered a superior WOMAC improvement compared to CS at short- (P = 0.002), mid- (P < 0.001, exceeding the MCID), and long-term (P < 0.001, exceeding the MCID) follow-ups. PRP offered a superior VAS improvement at mid- (P < 0.001, exceeding the MCID) and long-term (P = 0.023) follow-ups. Conclusion: CS injections for knee OA offer similar results to HA and PRP only at short term, while there is an overall superiority of PRP at longer follow-ups. This difference is not only statistically significant but also clinically relevant in favour of PRP.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu